SCHEMBL2084699

SCHEMBL2084699

Cc1cnc(CN)c(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGBL2 Q5U5Z8 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
LOXL2 Q9Y4K0 2/20 0.33
POLQ O75417 1/20 0.33
CACNA1H O95180 1/20 0.33
SSTR4 P31391 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LOX P28300 1/20 0.33
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
RAC1 P63000 1/20 0.31
PAK1 Q13153 1/20 0.31
DPP4 P27487 4/20 0.31
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24424327 0.79 IDO1 (0.36) AGBL2LOXL2POLQCACNA1HLOX
SCHEMBL29585366 0.79 IDO1 (0.36) AGBL2LOXL2POLQCACNA1HLOX
SCHEMBL21031169 0.79 TRPA1 (0.36) AGBL2POLQCACNA1HSSTR4RXRA
SCHEMBL2067677 0.78 HTT (0.35) LOXL2POLQCACNA1HSSTR4LOX
SCHEMBL16823599 0.78 L3MBTL1 (0.38) LOXL2CACNA1HHSD17B10LOXPRMT5
SCHEMBL24424273 0.77 CYP11B1 (0.39) CACNA1HDPP4PDK2RXRAGRIN1
Hydrochloric Acid SCHEMBL16165952 0.76 L3MBTL1 (0.38) LOXL2CACNA1HHSD17B10LOXPRMT5
SCHEMBL11890838 0.75 NOS3 (0.54) NOS3NOS1NOS2HPGDHSD17B10
SCHEMBL13732029 0.75 NOS3 (0.39) AGBL2NOS3NOS1NOS2LOXL2
SCHEMBL2082753 0.74 NOS3 (0.52) AGBL2NOS3NOS1NOS2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-20160052936-A1 SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
EP-2984092-A1 SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS Bayer Pharma Aktiengesellschaft (DE) 2016-02-17 EP disclosed
WO-2014166958-A1 SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-10-16 WO disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052936-A1 SPIROINDOLINE DERIVATIVES FOR USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS GNRHR, FSHR, PRLHR AGBL2 4681/4885NOS3 2255/4885NOS1 3625/4885
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 AGBL2 3707/4885NOS3 1323/4885NOS1 1421/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 AGBL2 3675/4885NOS3 2350/4885NOS1 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.